<DOC>
	<DOCNO>NCT02575950</DOCNO>
	<brief_summary>An exploratory Phase 2 , single , centre , prospective , randomize , placebo-controlled , double-blinded , split-pace ( left/right ) design trial evaluate efficacy tolerability LEO 43204 adult moderate severe acne .</brief_summary>
	<brief_title>Explorative Trial Evaluating Efficacy Tolerability LEO43204 Moderate Severe Acne</brief_title>
	<detailed_description />
	<mesh_term>Acne Vulgaris</mesh_term>
	<criteria>Subjects diagnose acne vulgaris face Fitzpatrick skin type IIII ( due lack safety data investigational product darker skin type ) Disease severity total lesion count similar TAs Disease severity grade moderate severe accord investigator 's global assessment ( grade 34 ) Age 18 35 year incl . Male female Female Subjects must either nonchildbearing potential childbearing potential confirm negative pregnancy test Subjects nodulocystic acne , acne conglobata , acne fulminans , secondary acne ( e.g . chloracne , druginduced acne ) Subjects previous history keloid formation postinflammatory hyperpigmentation Systemic retinoids within 12 month systemic antibiotic within 1 month Day 1 Topical retinoids within 3 month Day 1 topical treatment and/or medicate product cosmetic opinion investigator may influence subject acne vulgaris ( include soap contain antibacterial agent benzoyl peroxide , keratinolytic agent salicylic acid , skin fresheners/astringents aftershave product ) within 1 month Day 1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>